Perspectives
Nature Reviews Cancer 4, 988-993 (December 2004) | doi:10.1038/nrc1507
Opinion: CpG island methylator phenotype in cancer
Jean-Pierre Issa1 About the author
Abstract
DNA hypermethylation in CpG-rich promoters is now recognized as a common feature of human neoplasia. However, the pathophysiology of hyper-methylation (why, when, where) remains obscure. Cancers can be classified according to their degree of methylation, and those cancers with high degrees of methylation (the CpG island methylator phenotype, or CIMP) represent a clinically and aetiologically distinct group that is characterized by 'epigenetic instability'. Furthermore, CIMP-associated cancers seem to have a distinct epidemiology, a distinct histology, distinct precursor lesions and distinct molecular features.
Author affiliations
-
Jean-Pierre Issa is at the Department of Leukemia, M. D. Anderson Cancer Center, Unit 425, 1515 Holcombe, Houston, Texas 77030, USA.
Email: jpissa@mdanderson.org
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
CIMPle origin for promoter hypermethylation in colorectal cancer?Nature Genetics News and Views (01 Jul 2006)
Touching baseNature Genetics News and Views (01 Jan 2005)
RESEARCH
Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo ? use of the human tyrosinase promoter with human enhancersCancer Gene Therapy Original Article
Genetic basis of salt-susceptibility in the Sabra rat model of hypertensionKidney International Original Article
See all 37 matches for Research